High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis.
High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis.
复制标题
直接作用抗病毒药物 8 周疗程对患有慢性丙型肝炎的青少年和儿童的高 SVR12：综合分析
DOI：
10.3389/fmed.2021.608760
复制
发表时间：
2021
影响因子：
3.9
通讯作者：
Yue M
中科院分区：
文献类型：
--
作者：
Fu Z;Dong C;Ge Z;Wang C;Zhang Y;Shen C;Li J;Zhu C;Wang Y;Huang P;Yue M
在成人慢性丙型肝炎患者中，8周的直接作用抗病毒(DAA)治疗有持续的病毒学应答率。我们进行了一项系统的回顾和荟萃分析，以比较8周和12/24周的DAA治疗对青少年和儿童慢性丙型肝炎的疗效和安全性。计算机检索PubMed、Web of Science和Cochrane数据库2017年1月1日至2020年8月28日的相关文章，并于2021年4月1日进一步筛选文献综述。用Freeman-Tukey双反正弦变换的固定/随机效应模型对SVR12的95%顺式的池比例进行了总结。亚群分析用于寻找异质性的来源。确定了36份相关出版物。12~17岁青少年SVR12和AE率分别为99.4%(95%CI：98.7~99.9)和34.7%(95%CI：31.9~37.6)。没有人因药物不耐受而停止治疗。此外，治疗12周和8/24周的SVR12青少年分别为99.3%(95%CI：98.4~99.9)和100%。12岁以下儿童合并SVR12发生率为98.9%(95%CI：97.3~99.8)，AEs和SAEs分别为51.6%(95%CI：47.0~56.2)和1.1%(95%CI：0.4~2.5)。最常见的不良反应是疲劳(28.4%)。治疗12周和8/24周的患儿SVR12分别为98.8%(95%CI：97.1~99.8)和100%。综上所述，DAA对CHC普遍有效，青少年和儿童对DAA的耐受性良好。在这一人群中，8周的疗程与12/24周的疗程同样有效和安全。
Direct-acting antiviral (DAA) treatment for 8 weeks has a sustained virological response rate in adults with chronic hepatitis C. We have conducted a systematic review and meta-analysis to compare the efficacy and safety of the 8-week vs. 12/24-week DAA treatment in adolescents and children with CHC. The PubMed, Web of Science, and Cochrane databases were searched for the relevant articles from January 1, 2017 to August 28, 2020 and further screened for literature reviews on April 1, 2021. Pool proportions with 95% CIs for SVR12 were summarized with fixed/random effects models using Freeman–Tukey double arcsine transformation. Subgroup analysis was used to explore the source of heterogeneity. Thirty-six relevant publications were identified. For adolescents aged 12–17 years old, the pooled SVR12 and AE rate were 99.4% (95% CI: 98.7–99.9) and 34.7% (95% CI: 31.9–37.6). No one discontinued treatment due to drug intolerance. In addition, the SVR12 adolescents treated for 12 and 8/24 weeks were 99.3% (95% CI: 98.4–99.9) and 100%, respectively. The pooled SVR12 rate, AEs, and SAEs for children younger than 12 years were 98.9% (95% CI: 97.3–99.8), 51.6% (95% CI: 47.0–56.2), and 1.1% (95% CI: 0.4–2.5), respectively. The most common AE was fatigue (28.4%). The SVR12 was 98.8% (95% CI: 97.1–99.8) and 100% for the pediatric patients treated for 12 weeks and 8/24 weeks, respectively. Taken together, DAAs are generally effective against CHC and well-tolerated by the adolescents and children. A treatment duration of 8 weeks is equally effective and safe as 12/24 weeks in this demographic group.
登录
查看更多内容
DOI：
10.1097/mpg.0000000000002139
发表时间：
2019-01-01
影响因子：
2.9
作者：
Dhiman, Radha K.;Grover, Gagandeep S.;Satsangi, Sandeep
通讯作者：
Satsangi, Sandeep
影响因子：
3.2
作者：
Fouad, Hanan M.;Sabry, Magda A.;Aziz, Hossam Abdel
通讯作者：
Aziz, Hossam Abdel
影响因子：
13.5
作者：
Jonas, Maureen M.;Squires, Robert H.;Sokal, Etienne
通讯作者：
Sokal, Etienne
影响因子：
2.2
作者：
Al-Kaaby, Ban Adil;Al-Ethawi, Abd El-Salam
通讯作者：
Al-Ethawi, Abd El-Salam
DOI：
10.1097/mpg.0000000000001838
发表时间：
2018-03-01
影响因子：
2.9
作者：
El-Shabrawi, Mortada H.;Abdo, Alaa M.;Yakoot, Mostafa
通讯作者：
Yakoot, Mostafa